CA2916231C - Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof - Google Patents

Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof Download PDF

Info

Publication number
CA2916231C
CA2916231C CA2916231A CA2916231A CA2916231C CA 2916231 C CA2916231 C CA 2916231C CA 2916231 A CA2916231 A CA 2916231A CA 2916231 A CA2916231 A CA 2916231A CA 2916231 C CA2916231 C CA 2916231C
Authority
CA
Canada
Prior art keywords
seq
psm
amino acid
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2916231A
Other languages
English (en)
French (fr)
Other versions
CA2916231A1 (en
Inventor
Mohammad Javad Aman
Rajan Prasad ADHIKARI
Sergey Shulenin
Frederick Wayne Holtsberg
Hatice KARAUZUM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abvacc Inc
Original Assignee
Abvacc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2916231(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abvacc Inc filed Critical Abvacc Inc
Publication of CA2916231A1 publication Critical patent/CA2916231A1/en
Application granted granted Critical
Publication of CA2916231C publication Critical patent/CA2916231C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2916231A 2013-06-19 2014-06-18 Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof Active CA2916231C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836959P 2013-06-19 2013-06-19
US61/836,959 2013-06-19
PCT/US2014/042999 WO2014205111A1 (en) 2013-06-19 2014-06-18 Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Publications (2)

Publication Number Publication Date
CA2916231A1 CA2916231A1 (en) 2014-12-24
CA2916231C true CA2916231C (en) 2024-02-06

Family

ID=52105236

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2916231A Active CA2916231C (en) 2013-06-19 2014-06-18 Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Country Status (7)

Country Link
US (2) US9815872B2 (enExample)
EP (1) EP3010535B1 (enExample)
JP (1) JP6632974B2 (enExample)
CA (1) CA2916231C (enExample)
DK (1) DK3010535T3 (enExample)
PT (1) PT3010535T (enExample)
WO (1) WO2014205111A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916231C (en) 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
WO2018037408A1 (en) * 2016-08-22 2018-03-01 Technion Research & Development Foundation Limited Antimicrobial peptides and uses thereof
EP3532618A4 (en) * 2016-10-27 2020-05-20 MedImmune, LLC SIGNAL POLYPEPTIDES FOR IMPROVED PROTEIN SECRETION
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
MX2020001046A (es) 2017-07-27 2020-08-06 Integrated Biotherapeutic Vaccines Inc Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.
CN115427433A (zh) 2020-12-18 2022-12-02 生物医学研究及生物制品公司 保护性葡萄球菌外毒素疫苗
US12370235B2 (en) 2021-03-04 2025-07-29 University Of Saskatchewan Synthetic, non-natural antimicrobial peptides inspired by Staphylococcus auricularis delta toxin
GR1010289B (el) * 2021-04-27 2022-08-29 Integrated Biotherapeutic Vaccines, Inc., Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
CN113234125B (zh) * 2021-05-10 2022-12-06 华东理工大学 自组装多肽、多肽水凝胶及其制备方法和用途
WO2023227563A1 (en) 2022-05-23 2023-11-30 Biomedizinische Forschung & Bio-Produkte AG Protective staphylococcal exotoxin vaccine
WO2023247747A1 (en) 2022-06-23 2023-12-28 Biomedizinische Forschung & Bio-Produkte AG Protective staphylococcal exotoxin vaccine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
AU761021B2 (en) * 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
WO2008154101A1 (en) * 2007-06-06 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
CA2916231C (en) 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Also Published As

Publication number Publication date
PT3010535T (pt) 2020-07-03
US20180148482A1 (en) 2018-05-31
DK3010535T3 (da) 2020-11-30
JP6632974B2 (ja) 2020-01-22
US20160185829A1 (en) 2016-06-30
JP2016522259A (ja) 2016-07-28
US10174085B2 (en) 2019-01-08
US9815872B2 (en) 2017-11-14
EP3010535A4 (en) 2017-03-01
EP3010535B1 (en) 2019-08-14
CA2916231A1 (en) 2014-12-24
EP3010535A1 (en) 2016-04-27
WO2014205111A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
AU2012214677B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
CA2857666C (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
US11421021B2 (en) Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
GR1010289B (el) Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
CA3066450C (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
NZ626762B2 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613